Published in J Clin Endocrinol Metab on July 01, 2004
Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol (2010) 1.34
Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab (2011) 1.04
Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab (2007) 1.03
Congenital generalized lipodystrophies--new insights into metabolic dysfunction. Nat Rev Endocrinol (2015) 0.96
Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab (2015) 0.94
Leptin in relation to the lipodystrophy-associated metabolic syndrome. Diabetes Metab J (2012) 0.85
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol (2015) 0.83
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab (2016) 0.80
Urocortin ameliorates diabetic nephropathy in obese db/db mice. Br J Pharmacol (2008) 0.79
Leptin therapy in lipodystrophy. Diabetologia (2009) 0.78
The renal phenotype of allopurinol-treated HPRT-deficient mouse. PLoS One (2017) 0.75
Metreleptin Treatment in Three Patients with Generalized Lipodystrophy. Clin Med Insights Case Rep (2017) 0.75
Effect of exogenous leptin on serum levels of lipids, glucose, renal and hepatic variables in both genders of obese and streptozotocin-induced diabetic rats. Iran J Basic Med Sci (2015) 0.75
Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation. Endocrinol Diabetes Metab Case Rep (2017) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science (2007) 9.86
The GPR54 gene as a regulator of puberty. N Engl J Med (2003) 9.54
Leptin-replacement therapy for lipodystrophy. N Engl J Med (2002) 7.78
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med (2003) 6.87
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest (2002) 5.83
Genetics of obesity in humans. Endocr Rev (2006) 5.42
Large, rare chromosomal deletions associated with severe early-onset obesity. Nature (2009) 5.20
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest (2002) 4.75
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
PPAR gamma and human metabolic disease. J Clin Invest (2006) 3.83
Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab (2008) 3.80
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A (2007) 3.76
The hormonal control of food intake. Cell (2007) 3.61
A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science (2004) 3.54
Significant linkage of BMI to chromosome 10p in the U.K. population and evaluation of GAD2 as a positional candidate. Diabetes (2006) 3.51
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Leptin regulates striatal regions and human eating behavior. Science (2007) 3.31
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res (2004) 3.17
Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. Lancet (2007) 3.12
The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest (2007) 2.97
Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med (2008) 2.86
Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A (2007) 2.85
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet (2011) 2.73
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
The use of U-500 in patients with extreme insulin resistance. Diabetes Care (2005) 2.68
A genome-wide association meta-analysis identifies new childhood obesity loci. Nat Genet (2012) 2.60
KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell (2013) 2.56
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med (2007) 2.56
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem (2007) 2.55
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab (2008) 2.53
Monogenic obesity in humans. Annu Rev Med (2005) 2.53
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A (2004) 2.41
A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci (2004) 2.39
Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation (2002) 2.30
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes (2003) 2.28
TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes (2007) 2.20
Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol (2003) 2.13
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum (2003) 2.11
Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet (2009) 2.09
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion (2003) 2.05
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol (2009) 2.03
Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes (2007) 2.01
Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr (2009) 1.98
A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet (2009) 1.95
Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) (2002) 1.95
Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes (2011) 1.91
Autoimmune forms of hypoglycemia. Medicine (Baltimore) (2009) 1.90
Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes (2005) 1.89
Hypothalamic-specific manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One (2010) 1.89
Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet (2003) 1.87
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int (2008) 1.86
High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract (2009) 1.81
Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med (2009) 1.80
Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo. Biochem J (2003) 1.79
Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology (2007) 1.78
Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science (2013) 1.76
The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. Diabetes (2005) 1.76
The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat (2006) 1.75
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet (2012) 1.74
Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab (2004) 1.73
Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest (2003) 1.73
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet (2013) 1.72
Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J Clin Endocrinol Metab (2007) 1.70
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology (2003) 1.69
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab (2006) 1.68
The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes (2008) 1.67
Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab (2004) 1.66
Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab (2003) 1.65